Journal Article
. 2021 Nov; 24(11):790-795.
doi: 10.3779/j.issn.1009-3419.2021.102.41.

[Clinical Trial Progress and Application of Immune Checkpoint Inhibitors 
in the Treatment of Small Cell Lung Cancer]

Huiqiu Zhang 1 Xiyang Li 1 Xichuan Li 1 Yanjun Su 2 
  • PMID: 34802211
  •     25 References


Small cell lung cancer (SCLC) is a neuroendocrine tumor with fast progression, high malignancy, easy recurrence, and extremely poor prognosis. In the past 30 years, the clinical treatment strategy of SCLC has been mainly chemotherapy and radiotherapy, but the curative effect is not significant; the current immunotherapy of SCLC has gradually entered the clinic and has made certain progress. Tumor immunotherapy includes immune checkpoint inhibitors, tumor vaccines, cytokines, chimeric antigen receptor T-cell immunotherapy (CAR-T) therapy, etc. Currently, immune checkpoint inhibitors are the most widely used. This article summarizes the principles of immune checkpoint inhibitors and related drugs, summarizes their domestic and foreign clinical trials progress in SCLC treatment, reviews the biomarkers used in the therapy, and discusses its future development direction.

Keywords: Biomarkers; Clinical trial progress; Immune checkpoint inhibitors; Immunotherapy; Lung neoplasms.

Immunotherapeutic approaches for small-cell lung cancer.
Wade T Iams, Jason Porter, Leora Horn.
Nat Rev Clin Oncol, 2020 Feb 15; 17(5). PMID: 32055013    Free PMC article.
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.
M Reck, I Bondarenko, +7 authors, T J Lynch.
Ann Oncol, 2012 Aug 04; 24(1). PMID: 22858559
Highly Cited.
Immune checkpoints in the tumor microenvironment.
Salman M Toor, Varun Sasidharan Nair, Julie Decock, Eyad Elkord.
Semin Cancer Biol, 2019 Jul 03; 65. PMID: 31265893
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, +28 authors, Jedd D Wolchok.
N Engl J Med, 2015 Jun 02; 373(1). PMID: 26027431    Free PMC article.
Highly Cited.
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.
Ana C Anderson, Nicole Joller, Vijay K Kuchroo.
Immunity, 2016 May 19; 44(5). PMID: 27192565    Free PMC article.
Highly Cited. Review.
[Present and Future of Efficacy Biomarkers in Immune Checkpoint Inhibitors 
of Small Cell Lung Cancer].
Yaning Yang, Yan Wang.
Zhongguo Fei Ai Za Zhi, 2020 Aug 11; 23(10). PMID: 32773012    Free PMC article.
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.
Carl M Gay, C Allison Stewart, +27 authors, Lauren Averett Byers.
Cancer Cell, 2021 Jan 23; 39(3). PMID: 33482121    Free PMC article.
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.
Patrick A Ott, Elena Elez, +5 authors, Janice M Mehnert.
J Clin Oncol, 2017 Aug 17; 35(34). PMID: 28813164
Highly Cited.
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.
Neal E Ready, Patrick A Ott, +17 authors, David R Spigel.
J Thorac Oncol, 2019 Oct 21; 15(3). PMID: 31629915
Highly Cited.
[Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer].
Benlin Huang, Yong Duan.
Zhongguo Fei Ai Za Zhi, 2019 Apr 25; 22(4). PMID: 31014443    Free PMC article.
[Immune Characteristics of Small Cell Lung Cancer].
Yan Zhu, Shikai Wu.
Zhongguo Fei Ai Za Zhi, 2020 Oct 19; 23(10). PMID: 33070515    Free PMC article.
Next generation of immune checkpoint therapy in cancer: new developments and challenges.
Julian A Marin-Acevedo, Bhagirathbhai Dholaria, +3 authors, Yanyan Lou.
J Hematol Oncol, 2018 Mar 17; 11(1). PMID: 29544515    Free PMC article.
Highly Cited. Review.
The Future of Immunotherapy in the Treatment of Cancer.
Lisa A Kottschade.
Semin Oncol Nurs, 2019 Sep 04; 35(5). PMID: 31477413
[Clinical Development of Immune Checkpoint Inhibitors in Patients with Small Cell Lung Cancer].
Shuang Zhang, Jingjing Liu, Ying Cheng.
Zhongguo Fei Ai Za Zhi, 2017 Sep 25; 20(9). PMID: 28935016    Free PMC article.
[A Reflection of the New Wave of Immunotherapy on the Clinical Study of 
Chinese Lung Cancer Immunotherapy].
Jingjing Liu, Shuang Zhang, Shuang Li, Ying Cheng.
Zhongguo Fei Ai Za Zhi, 2017 Oct 25; 20(10). PMID: 29061217    Free PMC article.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Jonathan W Goldman, Mikhail Dvorkin, +23 authors, CASPIAN investigators.
Lancet Oncol, 2020 Dec 08; 22(1). PMID: 33285097
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Leora Horn, Aaron S Mansfield, +19 authors, IMpower133 Study Group.
N Engl J Med, 2018 Oct 04; 379(23). PMID: 30280641
Highly Cited.
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
Yu-Jung Kim, Bhumsuk Keam, +9 authors, Dae Seog Heo.
Lung Cancer, 2019 Sep 09; 136. PMID: 31494530
[New Advances in the Treatment for Small Cell Lung Cancer].
Xiaoxia Cui, Peng Song, Li Zhang.
Zhongguo Fei Ai Za Zhi, 2019 Jun 15; 22(6). PMID: 31196369    Free PMC article.
[Immunotherapy Advances in Small Cell Lung Cancer].
Yangyang Xu, Ping Zhan, Yong Song.
Zhongguo Fei Ai Za Zhi, 2020 Aug 06; 23(11). PMID: 32752583    Free PMC article.
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.
Evan J Lipson, Charles G Drake.
Clin Cancer Res, 2011 Sep 09; 17(22). PMID: 21900389    Free PMC article.
Highly Cited. Review.
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
Matthew D Hellmann, Margaret K Callahan, +13 authors, Scott J Antonia.
Cancer Cell, 2018 May 08; 33(5). PMID: 29731394    Free PMC article.
Highly Cited.
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032.
Neal Ready, Anna F Farago, +12 authors, Scott J Antonia.
J Thorac Oncol, 2018 Oct 14; 14(2). PMID: 30316010    Free PMC article.
Highly Cited.